Table 2 Clinicopathologic variables of the training and validation sets

Age (%)

  ≤ 65 years

21 (32.81)

18 (38.30)

  > 65 years

43 (67.19)

29 (61.70)

Sex (%)

 Male

33 (51.56)

28 (59.57)

 Female

31 (48.44)

19 (40.43)

BMI (%)

  ≤ 18 kg/m²

9 (14.06)

7 (14.89)

 18 ~ 25 kg/m²

42 (65.62)

31 (65.96)

  ≥ 25 kg/m²

13 (20.31)

9 (19.15)

Clinical T stage (%)^a

 2

9 (14.06)

6 (12.77)

 3

32 (50.00)

26 (55.32)

 4

23 (35.94)

15 (31.91)

Clinical N stage (%)^a

 0

17 (26.56)

6 (12.77)

 1

23 (35.94)

24 (51.06)

 2

16 (25.00)

11 (23.40)

 3

8 (12.50)

6 (12.77)

Neutrophil count (N) × 10⁹/L

3.6 (2.6–4.3)

3.3 (2.6–4.0)

Lymphocyte count (L) × 10⁹/L

1.6 (1.3–.0)

1.7 (1.3–2.0)

Platelet count (P) × 10⁹/L

211.0 (157.8–260.8)

188.0 (159.0–258.0)

 NLR

2.2 (1.3–3.0)

1.7 (1.5–2.8)

 PLR

125.0 (90.9–166.7)

111.1 (80.1–166.7)

Hemoglobin (Hb) g/L

123.5 (104.8–138.0)

132.0 (111.0–142.0)

Albumin (Alb) g/L

37.9 ± 3.4

38.7 ± 3.4

 AFP ng/L

2.3 (1.7–3.5)

2.7 (1.7–4.1)

 CEA ng/L

1.5 (0.7–3.1)

1.3 (0.6–2.5)

 CA125 ng/L

7.7 (5.1–16.3)

7.9 (4.8–13.2)

 CA242 ng/L

4.1 (3.0–9.8)

3.9 (2.6–9.7)

 CA199 ng/L

8.9 (6.2–27.7)

7.8 (4.0–22.0)

 CA724 ng/L

3.0 (1.4–6.3)

2.1 (1.4–3.8)

 CLDN18.2

2.0 (0.0–8.0)

4.0 (2.0–7.0)

Tumor location (%)

 Upper

26 (40.6)

15 (31.9)

 Middle

15 (23.4)

10 (21.3)

 Lower

23 (35.9)

22 (46.8)

Occult peritoneal metastasis (%)

 No

32 (50.0)

31 (66.0)

 Yes

32 (50.0)

16 (34.0)

Lauren classification (%)

 Diffuse type

31 (48.4)

11 (23.4)

 Intestinal type

18 (28.1)

19 (40.4)

 Mixed type

15 (23.4)

17 (36.2)

Tumor differentiation type (%)

 Undifferentiated type

38 (59.4)

23 (48.9)

 Mixed type

19 (29.7)

14 (29.8)

 Differentiated type

7 (10.9)

10 (21.3)